RxDoctor Payments Data

Gary Berman, MD

Clinical & Laboratory Immunology · Minneapolis, MNNPI 1609836121

Payments from drug & device makers

$24,357,785in general payments, 2019–2025

Across 3,158 payments — averaging $7713.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$21.5M
  • AbbVie$720K
  • Amgen$327K
  • Teva Pharmaceuticals USA, Inc.$318K
  • Siemens Medical Solutions USA, Inc.$257K
  • H. Lundbeck A S$234K
  • plus $970K from 24 others
$14,674in research payments, 2019–2025

Across 28 payments — averaging $524.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$12K
  • Sanofi Pasteur Inc.$2K
  • Regeneron$1K
  • Teva Pharmaceuticals USA, Inc.$89

What the payments were for

  • Consulting fees$32,54213%
  • Speaking & faculty fees$170,79171%
  • Grants$850%
  • Travel & lodging$32,65314%
  • Food & beverage$5,3172%
  • Education$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical & laboratory immunology providers in Minnesotato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$49,951
Medicare patients
112
Services billed
1,745

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter72$63,474
Breo ElliptaFluticasone/Vilanterol111$56,366
Zileuton ErZileuton12$56,049
Dupixent PenDupilumab14$53,097
XolairOmalizumab28$51,884
Ajovy AutoinjectorFremanezumab-Vfrm21$39,975
Advair HfaFluticasone Propion/Salmeterol50$29,213
Fluticasone-SalmeterolFluticasone Propion/Salmeterol87$24,329
DuleraMometasone/Formoterol30$19,525
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$19,303
Wixela InhubFluticasone Propion/Salmeterol50$12,364
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate35$11,199
Emgality PenGalcanezumab-Gnlm14$9,612
Arnuity ElliptaFluticasone Furoate29$8,350
SymbicortBudesonide/Formoterol Fumarate25$7,850

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$53,636$128,190212 claims
AstraZenecaBreztri Aerosphere, Symbicort$26$27,15250 claims
MerckDulera$31,728$19,52530 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$318,023$4,48915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical & laboratory immunology providers in Minnesotaon file to place this against a meaningful peer group, so we don't.

Other clinical & laboratory immunology in Minneapolis

Where these figures come from

Is this you, or does something look wrong? →